Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905733 | 0.88 | KEAP1 (0.50) | KEAP1KDM4EALDH1A1HSD17B10MCOLN3 | |
| SCHEMBL16200786 | 0.86 | KEAP1 (0.36) | KEAP1PTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL16200791 | 0.84 | CYP1A2 (0.33) | — | |
| SCHEMBL9900628 | 0.83 | HSPB1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL23780536 | 0.82 | — | — | |
| SCHEMBL23279398 | 0.82 | KEAP1 (0.32) | KEAP1KDM4EMCOLN3 | |
| SCHEMBL16650573 | 0.80 | KEAP1 (0.31) | KEAP1 | |
| SCHEMBL16649854 | 0.79 | HTR2C (0.32) | KEAP1 | |
| SCHEMBL15534678 | 0.79 | KMT2A (0.37) | — | |
| SCHEMBL18195681 | 0.78 | MMP13 (0.32) | KDM4EMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | disclosed |
| US-9833452-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | disclosed |
| US-9422272-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-08-23 | — | — | US | disclosed |
| US-20150336936-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2015-11-26 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336936-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | KEAP1 1008/4885PTGS1 1928/4885PTGS2 2205/4885 |
| US-20160317537-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | KEAP1 1008/4885PTGS1 1928/4885PTGS2 2205/4885 |
| US-20140323508-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | KEAP1 580/4885PTGS1 1453/4885PTGS2 1846/4885 |
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | KEAP1 2099/4885PTGS1 4703/4885PTGS2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.